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ABSTRACT
Treatment of multidrug-resistant Gram-positive
infections continues to challenge clinicians as
the emergence of new resistance mechanisms
outpaces introduction of novel antimicrobial
agents. Tedizolid phosphate is a next-
generation oxazolidinone with activity against
both methicillin-resistant Staphylococcus aureus
and vancomycin-resistant Enterococcus spp.
Tedizolid has consistently shown potency
advantages over linezolid against Gram-
positive microorganisms including those with
reduced susceptibility to linezolid. Of particular
significance, minimum inhibitory
concentrations of tedizolid appear to be
largely unaffected by the chloramphenicol–
florfenicol resistance (cfr) gene, which has been
implicated in a number of published linezolid-
resistant organism outbreaks. Tedizolid
phosphate also has been found to have a
favorable pharmacokinetic profile allowing for
once-daily dosing in both oral and intravenous
forms. Potency and pharmacokinetic
advantages have allowed for lower total daily
doses of tedizolid, compared to linezolid, being
needed for clinical efficacy in the treatment of
acute bacterial skin and skin structure infections
(ABSSSI). The decreased total drug exposure
produced may in part be responsible for a
decrease in the observed adverse effects
including thrombocytopenia. Tedizolid
phosphate is currently indicated for the
treatment of ABSSSI and under investigation
for the treatment of nosocomial pneumonia.
Although much of the role of tedizolid remains
to be defined by expanding clinical experience,
tedizolid is likely a welcomed addition to the
mere handful of agents available for the
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are commonly causative of nosocomial
infections and are associated with significant
morbidity and mortality [1]. Of particular
concern to clinicians, methicillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-
resistant enterococci (VRE) remain sensitive to
few antimicrobial agents available for the
treatment of serious infections [2–4].
Daptomycin and linezolid have been
increasingly utilized over the past 15 years,
and reduced susceptibility to each of these
drugs has emerged among staphylococci and
enterococci [5–8]. Though resistance to these
agents is currently rare, expanding the
antibiotic armamentarium available for the
treatment of serious MRSA and VRE infections
has become increasingly important.
Oxazolidinones are a synthetic class of
antimicrobials, developed over the past 30 years
by numerous pharmaceutical companies [9].
Linezolid, the first oxazolidinone approved for
use in clinical practice, has activity against
both multidrug-resistant staphylococci and
enterococci. Currently indicated for the
treatment of complicated and uncomplicated
skin and skin structure infections (cSSSI),
community-acquired and nosocomial
pneumonia, as well as infections caused by
VRE, linezolid has found widespread utilization
in clinical practice [10].
Tedizolid phosphate (formerly torezolid;
Cubist Pharmaceuticals) is the first of the next
generation of oxazolidinones to obtain Food
and Drug Administration (FDA) approval. A
number of similarities exist between tedizolid
and its predecessor linezolid. However, initial
experience with tedizolid has shown advantages
in antimicrobial potency against key organisms
including those with reduced susceptibility to
linezolid, lower incidence of adverse effects over
short courses of therapy, and favorable
pharmacokinetics. This article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
STRUCTURE AND MECHANISM
OF ANTIMICROBIAL ACTIVITY
Throughout the development of the
oxazolidinones, the class pharmacophore was
increasingly refined by a series of structure–
activity relationship studies [9]. Linezolid
demonstrates several structural features
strongly associated with enhanced
antimicrobial potency. The addition of the
N-aryl group (B-ring) to the oxazolidinone ring
(A-ring) is essential for activity and is further
enhanced by both a meta-fluorine and para-
oriented electron withdrawing or unsaturated
group (C-ring). Linezolid, as well as a number of
oxazolidinones currently undergoing clinical
investigation, features an acetamidomethyl
sidechain on C-5 of the oxazolidinone ring.
The incorporation of this sidechain has
displayed potency benefits among both Gram-
positive organisms and mycobacterium [11].
The approval of tedizolid phosphate marks
not only the first of a new generation of
oxazolidinone antimicrobials, but also a
departure from previously held structure–
activity relationships (Fig. 1). While earlier
studies found a hydroxymethyl sidechain in
the C-5 position offered decreased potency, it
was later shown that this could be
circumvented with the addition of a fourth
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para-oriented ring structure (D-ring) [12]. It is
believed the D-ring structure adds additional
sites for hydrogen bonding and further
stabilizes interactions with the target site.
Interestingly, with these structural features
bookending the structure of tedizolid, an
antimicrobial activity several fold above that
of linezolid was achieved. The utilization of the
phosphorylated prodrug, tedizolid phosphate,
enables significantly improved solubility in
water and excellent oral bioavailability while
also masking the C-5 hydroxymethyl from
interactions with monoamine oxidase (MAO)
[13]. The phosphate group is readily cleaved in
blood by serum phosphatase and does not
impair antimicrobial potency [9, 14].
Oxazolidinones exert antimicrobial activity
through inhibition of protein synthesis,
binding to the V-domain of the 23S rRNA
component of the 50S ribosomal subunit. This
inhibition produces primarily bacteriostatic
antimicrobial activity at clinically relevant
concentrations. Extensive interactions between
oxazolidinones and the A-site of the peptidyl-
transferase center (PTC) block the alignment of
incoming aminoacyl-tRNA and halt peptide
elongation [15]. Although the hypothesized
interaction sites for oxazolidinones are at least
partially unique to this class of protein synthesis
inhibitors, there appears to be a degree of
overlap with other antimicrobials such as
chloramphenicol, clindamycin, and
streptogramin A [16]. As with other protein
synthesis inhibitors such as clindamycin, some
studies have suggested that oxazolidinones may
decrease the production of certain toxins
among staphylococci and streptococci [17, 18].
However, further investigation will be required
to identify the clinical utility of this effect.
SUSCEPTIBILITY
Linezolid has demonstrated significant activity
against a number of Gram-positive organisms as
well as mycobacterium. The most recent data
from the Zyvox (Pfizer) Annual Appraisal of
Potency and Spectrum (ZAAPS) reports the
susceptibility of S. aureus, coagulase-negative
staphylococci (CoNS), enterococci, and
streptococci, totaling 7972 isolates, collected
across the five continents in 2012 (Table 1). In
this study, the 90% minimum inhibitory
concentration (MIC90) for methicillin-
susceptible S. aureus (MSSA), MRSA,
Enterococcus faecium (including vancomycin-
resistant isolates), and Enterococcus faecalis was
found to be 2 mg/L. CoNS and b-hemolytic
streptococci had MIC90 of 1 mg/L. Linezolid
non-susceptible isolates were reported but
occurred very rarely, with the largest
proportion (0.9%) among CoNS [19].
Tedizolid phosphate exhibits a spectrum of
activity similar to that of linezolid. However,
the potency of tedizolid against Gram-positive
organisms has been reported to be two- to
eightfold higher than that of linezolid
throughout development. Recently, tedizolid
susceptibility among 6884 isolates from the
USA and 11 European countries was examined.
Fig. 1 Structures of tedizolid, tedizolid phosphate, and
linezolid
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In general, tedizolid displayed MIC90
approximately fourfold lower than those of
linezolid. Organisms with decreased
susceptibility to linezolid also commonly have
elevated tedizolid MIC. Among isolates non-
susceptible to linezolid, tedizolid MIC (ranging
from 0.5 to 8 mg/L) were 8- to 16-fold lower
than those of linezolid, varying with specific
resistance mechanisms (Table 2). Interestingly,
for three of the four S. aureus isolates harboring
cfr-mediated resistance, tedizolid MIC remained
at 0.5 mg/L, with the fourth isolate having an
MIC of 1 mg/L.
The current FDA approved clinical
breakpoint for tedizolid susceptibility
is B0.5 mg/L.
MECHANISMS OF RESISTANCE
Although it was originally anticipated that the
fully synthetic nature of the oxazolidinone class
would circumvent preexisting pools of
resistance, the first isolates of Gram-positive
organisms with resistance to linezolid appeared
during preclinical trials [20]. Additionally, a
clinical isolate of S. aureus was found to be
resistant to linezolid after acquisition of a
previously known and naturally occurring
resistance mechanism [21]. Emergence of
clinical isolates with reduced susceptibility to
linezolid has nonetheless remained relatively
rare for over a decade. Resistance rates vary
slightly by region, but remain under 1% across
staphylococci and enterococci. Resistance is
most frequently reported in individual patients
following repeated or extended exposures to
linezolid, although horizontal transfer has led
to outbreaks of organisms with reduced
linezolid susceptibility at institutions with
higher linezolid utilization [8, 22]. Reduced
susceptibility to oxazolidinones is most
frequently associated with either point
mutations within the ribosomal complex or
the acquisition of the chloramphenicol–florfenicol
resistance (cfr) gene.
Point mutations within either the 23S rRNA
or ribosomal proteins L3 and L4 were the first
widely recognized mechanisms of reduced
oxazolidinone susceptibility. As staphylococci
and enterococci typically possess five to six and
four to six copies of 23S rRNA genes,
respectively, multiple mutations often must be
acquired before MIC climb above clinical
breakpoints. The G2576T mutation is a
Table 1 Comparative activity of oxazolidinones against
Gram-positive organisms [34, 56]
Organism (n) Linezolid Tedizolid
MIC50 MIC90 MIC50 MIC90
Staphylococcus aureus
MRSA (1770) 2 2 0.25 0.5
MSSA (2729) 2 2 0.25 0.5
Coagulase-negative
staphylococci (537)
1 NAa B0.12 0.25
Enterococcus spp.
E. faecalis (221) 1 2 0.25 0.5
E. faecium (634) 2 2 0.25 0.5
VRE (163) 2 2 0.25 0.5




1 1 0.12 0.25
S. pneumoniae 1 2 0.25 0.25
All values are given in mg/L
MIC50 50% minimum inhibitory concentration, MIC90
90% minimum inhibitory concentration, MRSA
methicillin-resistant Staphylococcus aureus, MSSA
methicillin-susceptible Staphylococcus aureus, VRE
vancomycin-resistant enterococci, VSE vancomycin-
susceptible enterococci
a MIC90 1 and 2 mg/L for S. epidermidis and other
coagulase-negative Staphylococcus spp., respectively
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notable exception, where a single copy
mutation can create resistant isolates [23]. This
genetic redundancy may at least in part be
responsible for the sustained activity of
linezolid. However, single copy mutations
have been shown to be relatively stable and
possess low fitness cost, making additional
mutations and more rapid emergence of
resistant isolates possible with multiple
exposures to linezolid [24]. This more rapid
emergence of resistance has been reported
clinically after as few as two courses of
linezolid [25].
L3 and L4 ribosomal proteins are located
proximally to the 23S rRNA, and mutations in
these proteins appear to disturb the interactions
between oxazolidinones and the PTC. This
mechanism of resistance may be less common
than others among staphylococci and
enterococci; however, a recent study of the
Center for Disease Control and Prevention’s
Active Bacterial Core surveillance found L4
mutations to be the only mechanism detected
among linezolid-resistant pneumococcus
(though only present in 3 of the 45,099
isolates tested) [26]. In staphylococci and
enterococci, modifications to L4 in particular
appear to have a clinically significant impact on
linezolid MIC, leading to a fourfold increase
when added to previously susceptible isolates
[27]. Additionally, L3 mutations have been
shown to restore fitness to organisms with
multiple 23S rRNA mutations, as well as
dramatically inflate MIC in the presence of the
cfr gene [28, 29].
Perhaps, the most worrisome of these
resistance mechanisms is the acquisition of the
cfr gene. This gene, previously best known for
leading to phenicol-resistant infections in
livestock, is often carried on mobile genetic
elements and has been shown to be
horizontally transferrable [30]. In fact, cfr has
now been detected in both Gram-positive and
Gram-negative organisms ranging from
Table 2 Comparative activity of oxazolidinones against Staphylococcus aureus with identiﬁed mechanisms of reduced
susceptibility [29, 34, 36, 57]
Mechanism (n) Number of isolates with MIC (% inhibited at speciﬁed concentration) Susceptible (%)
0.5 1 2 4 8 16 32 64 128
23S rRNA mutations (17)
Tedizolid – 1 (6) 9 (59) 4 (82) 2(94) 1 (100) – – – 0
Linezolid – – – 1 (6) 1(12) 7 (53) 4 (77) 4 (100) – 0
L3 or L4 modiﬁcations (6)
Tedizolid 1 (17) 2 (50) 3 (100) – – – – – – 17
Linezolid – – 1 (17) 1 (33) 4(100) – – – – 0
cfr positive (13)
Tedizolid 11 (85) 2 (100) – – – – – – – 85
Linezolid – – – – 3(23) 9 (92) 1 (100) – – 0
Multiple mechanisms (5)
Tedizolid – 2 (40) 3 (100) – – – – – – 0
Linezolid – – – – – – 2 (40) 3 (100) – 0
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enterococci to Enterobacteriaceae [31]. The cfr
gene encodes for the RNA methyltransferase
Cfr, which adds a second methyl group at
A2503 of the 23S rRNA. This additional
methylation is known to occupy a portion of
the PTC binding pocket which leads to
decreased affinity for a number of protein
synthesis inhibitors. CM05, the first clinical
isolate observed to possess Cfr-mediated
linezolid resistance, also possessed the ermB
methyltransferase gene. The combination of
these genes under regulation of a single
promoter became known as the mlr operon
and essentially abolishes the activity of all
protein synthesis inhibitors common to
clinical practice today [32, 33]. To date, the
mlr operon has not been reported to be present
in other clinical isolates.
Cfr-mediated A2503 methylation, in the case
of the oxazolidinones, overlaps with the site
normally occupied by the C-5 sidechain. As
such, linezolid MIC have been observed to
increase two- to fourfold in organisms
acquiring the cfr gene [29]. Conversely,
tedizolid MIC are typically stable in the
presence of Cfr methylation [34–36]. This is
believed to be due to the fact that the
hydroxymethyl C-5 sidechain is smaller and
more flexible than acetamidomethyl sidechain
of linezolid [36]. The preserved potency of
tedizolid among cfr isolates suggests it may
remain useful against some linezolid-resistant
organisms. However, clinical experience has yet
to verify this in vitro advantage as clinically
significant.
PHARMACOKINETICS
The pharmacokinetic profile of tedizolid
phosphate has been well evaluated in Phase I
and Phase II studies. When 200 mg of tedizolid
phosphate is administered intravenously,
conversion to the active form by serum
phosphatase begins immediately. The
maximum serum concentration (Cmax) of
tedizolid, 2.6 mg/L, is observed at
approximately 1 h following initiation of
infusion. Clearance in healthy adults is about
5 L/h, with an elimination half-life of 12 h.
With daily administration, the total area under
the curve at 24 h (AUC0–24) is roughly 30 mg h/
L. Seventy-five to 80% of tedizolid is bound to
serum proteins [37, 38].
When administered orally, tedizolid
phosphate has an absolute bioavailability of
91%. Cmax and AUC0–24 are only slightly
decreased compared to intravenous
administration (2 mg/L and 26 mg h/L,
respectively, under fasting conditions). The
time to Cmax is 2 h when administered under
fasting conditions, but increases to 8 h in
patients having recently eaten a full meal. The
fed state also appears to blunt Cmax values, but
AUC0–24 remains unchanged [37, 39].
Tedizolid pharmacokinetic parameters have
also been studied in patients with various
degrees of renal or hepatic dysfunction. When
intravenously administered to patients with
severe renal impairment, 200 mg tedizolid
phosphate produced Cmax and AUC0–24
minimally changed from the matched control
group. Cmax and AUC0–24 were however reduced
by approximately 15% and 25%, respectively, in
patients undergoing hemodialysis. Four-hour
hemodialysis sessions using a high-flux filter
were observed to remove less than 10% of
tedizolid doses administered intravenously
immediately prior. Among patients with
moderate and severe hepatic dysfunction,
200 mg of orally administered tedizolid
produced similar Cmax values, but 22% and
34% higher AUC0–24, respectively [38].
Currently, no dosage adjustment is
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recommended for patients with either renal or
hepatic dysfunction.
Much like linezolid, the volume of
distribution for tedizolid is relatively large.
Central compartment volume of distribution is
approximately 70 L, with the volume of
distribution for the periphery ranging from 13
to 25 L [37, 40, 41]. Cmax in soft tissues
including muscle and adipose approximate
free drug concentrations seen in plasma, with
modestly elevated free AUC (fAUC) compared
to plasma [42]. Studies examining the
pulmonary distribution of tedizolid in both
various murine and healthy volunteer
populations have reported significant
accumulation of tedizolid. While AUC0–24 for
linezolid in epithelial lining fluid (ELF) have
been reported to be around fivefold those seen
in plasma, tedizolid was found to have an ELF
AUC0–24 40-fold higher (approximately
100 mg h/L for a 200 mg dose) than plasma.
Alveolar macrophages also appear to
accumulate tedizolid tenfold higher than
linezolid relative to respective plasma
concentrations [43]. Given the concentration-
dependent activity of oxazolidinones, this
increased pulmonary exposure of tedizolid
may be therapeutically advantageous for the
treatment of pulmonary infections.
PHARMACODYNAMICS
Oxazolidinones, including both linezolid and
tedizolid, appear to have pharmacodynamic
profiles best described by the fAUC0–24 to MIC
ratio (fAUC0–24:MIC). Initial modeling with
linezolid suggested a pharmacodynamic target
of 58 mg h/L, which was subsequently echoed
by pharmacodynamic evaluation of linezolid
clinical outcomes in the treatment of both skin
and soft tissue infections and pneumonia [44,
45]. While early work with tedizolid suggested
pharmacodynamic targets of approximately 47
and 20 mg h/L for bacterial stasis in classic
neutropenic models of murine thigh infections
and pneumonia, respectively, the dose of
tedizolid phosphate selected for late-stage
clinical trials was significantly lower than that
required to meet these targets [46, 47]. This was
in large part due to the clinical response
observed with 200 mg daily dosing in Phase II
trials, and later supported by pharmacodynamic
evaluations investigating the impact of
granulocytes on the activity of tedizolid. In an
assessment of the pharmacodynamics of
tedizolid in a non-neutropenic murine thigh
infection model, a 16-fold lower dose to achieve
bacterial stasis at 24 h was required compared to
neutropenic mice. This dose would be estimated
to achieve an fAUC0–24:MIC of approximately
3 mg h/L [48]. It was also observed that in the
presence of granulocytes, tedizolid reduced
bacterial burden of MRSA by 3.5 log10CFU and
4.7 log10CFU at 48 and 72 h, respectively, when
accounting for the direct activity of
granulocytes without tedizolid therapy [49].
This seemingly bactericidal activity contrasts
the normal expectation of bacteriostasis with
oxazolidinone treatment. These data, along
with the non-inferiority of tedizolid compared
to linezolid in Phase II and III clinical trials,
support the use of the 200 mg daily dosing of
tedizolid for acute bacterial skin and skin
structure infections (ABSSSI).
EARLY CLINICAL EXPERIENCE
A single Phase II randomized, double-blind,
dose-ranging clinical trial was completed to
evaluate the efficacy, safety, and
pharmacokinetic profile of tedizolid for cSSSI
[41]. Patients enrolled were aged 18–75 years
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with deep extensive cellulitis, surgical or post-
traumatic wounds, or an abscess, caused by
Gram-positive pathogens with systemic signs/
symptoms of infection. Patients were
randomized 1:1:1 to receive 200, 300, or
400 mg of oral tedizolid phosphate dosed once
daily for 5–7 days as determined by the
investigator based upon clinical response. The
primary outcome evaluated was clinical
response in the clinically evaluable (CE) and
clinically modified intent-to-treat (cMITT)
populations at the 7–14 days post-treatment
test-of-cure (TOC) visit. Clinical cure was
defined as resolution or improvement of cSSSI
symptoms such that no further treatment was
required.
Baseline characteristics were similar between
groups, with the majority of patients being
Caucasian (76%), male (65%), and with a mean
age of 36 years [41]. The most common
infection type was abscess (77%) with the
majority of lesions between 10 and 20 cm
(45%) in size. S. aureus was the most common
isolated pathogen (90%) with 81% of these
isolates being MRSA. The mean duration of
therapy was 6.4 days, and 95% of patients
completed treatment.
Primary outcomes were similar between
groups for each population, with clinical cure
rates of 88.9%, 88.9%, and 85.5% in cMITT,
98.2%, 94.4%, and 94.4% in CE, and 100%,
93.2%, and 95.7% in the microbiologically
evaluable populations for the 200, 300, and
400 mg groups, respectively [41]. Similar cure
rates were also seen among the infection type
subgroups and by baseline pathogen.
Microbiologic eradication rates were also
similar, ranging from 92.6% to 100% for
MRSA in all three dosing groups, and 100%
eradication in the severe infection group
specifically. Adverse events were reported
similarly between groups with any adverse
event reported in 66.7% of those taking
200 mg, 69.8% on 300 mg, and 71.0% on
400 mg doses. The most common adverse
events were nausea, secondary abscess,
headache, and vomiting, and no patients
discontinued therapy due to adverse events.
The pharmacokinetic data collected resulted in
a model displaying linear kinetics with an
estimated total clearance of 8.28 L/h,
distribution clearance of 2.95 L/h, a central
compartment volume of 71.4 L, and a
peripheral compartment volume of 27.9 L.
Tedizolid phosphate studied at 200, 300, and
400 mg once daily was found to be effective,
safe, and well tolerated when used for 5–7 days
for cSSSI [41]. Clinical cure rates were similar
between treatment groups, and the 200 mg
daily dose was considered to be the lowest
efficacious dose, supporting the use of this dose
for future trials involving skin and skin
structure infections.
Two Phase III clinical trials, ESTABLISH-1
(ClinicalTrials.gov #NCT01170221) and
ESTABLISH-2 (ClinicalTrials.gov
#NCT01421511), were conducted to compare a
5-day course of tedizolid phosphate to a 10-day
course of linezolid in patients with ABSSSI [50–
52]. The ESTABLISH studies were randomized,
double-blind, double-dummy, multicenter,
multi-national, and non-inferiority trials with
patients stratified by clinical syndrome,
geographic region, and fever (ESTABLISH-1
only). Patients were randomized 1:1 to either
receive tedizolid phosphate 200 mg daily or
linezolid 600 mg twice daily. ESTABLISH-1
evaluated oral therapy only for this indication,
while patents in ESTABLISH-2 received two or
more doses of intravenous therapy prior to
having the option of being switched to oral
therapy. Patients included were aged 18 years or
older in ESTABLISH-1 and 12 years or older in
ESTABLISH-2, who had an ABSSSI (cellulitis/
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erysipelas, major cutaneous abscess, or wound
infection) caused by a Gram-positive pathogen,
and whose lesion area was at least 75 cm2. Early
clinical response in the intention-to-treat (ITT)
population at 48–72 h was selected as the
primary end point, but was defined slightly
differently in the two trials due to
recommendations presented in the 2013 FDA
guidance for ABSSSI. For the pooled analysis,
the primary efficacy outcomes measured were a
reduction of C20% in lesion area, receipt of
concomitant systemic antibiotics with Gram-
positive activity, and all-cause mortality within
72 h [52]. Secondary end points included
clinical response at day seven, end of therapy
(EOT) visit between days 11–13, and post-
therapy evaluation (PTE) visit at 7–14 days
after the EOT (days 18–25), as well as safety
outcomes assessed throughout.
Baseline characteristics were similar between
studies and treatment groups with the majority
of patients being men (63%) with a median age
of 44 years [50–52]. Cellulitis/erysipelas was the
most common type of ABSSSI (46%) and was
most frequently located on either lower (41%)
or upper extremities (34%). The pathogen
isolated most frequently was S. aureus (82%),
with 43% of those being MRSA and 57% being
MSSA. A numerically higher percentage of
patients enrolled in ESTABLISH-1 were from
North America (81%) compared to those
enrolled in ESTABLISH-2 (47%), leading to
higher percentages of patients with MRSA
isolated in ESTABLISH-1 than ESTABLISH-2
(43% compared to 28%). Tedizolid met the
criteria for non-inferiority in both trials, with
similar early clinical response in the pooled ITT
population of 81.6% for tedizolid and 79.4%
for linezolid (95% CI -2.0 to 6.5). This
similarity between groups at early clinical
response was also seen between all pre-
specified subgroups, including key causative
pathogen, with a response of 85.1% and 80.7%
observed against S. aureus for tedizolid and
linezolid, respectively. Additionally, secondary
end points of clinical response at EOT were
also similar between groups with 87.0% for
tedizolid and 87.9% for linezolid (95% CI
14.4–2.7), as well as investigator-assessed
clinical response at PTE, with a response of
86.7% for tedizolid and 86.8% for linezolid
(95% CI -3.8 to 3.6).
Treatment-emergent adverse events (TEAE)
were reported in 43% of patients overall, with
the most common events being nausea,
headache, and abscess [50–52].
Gastrointestinal adverse events were the most
frequently reported and were more likely to
occur in the linezolid group (23% compared to
16%; P = 0.0015). A difference in the
occurrence of hematologic laboratory
abnormalities between groups was also
reported. The most prominent difference was
seen in the incidence of thrombocytopenia
(defined as platelets\150,000 cells/mm3), with
3.7% versus 5.6% (P = 0.585) at 7–9 days, and
4.9% versus 10.8% (P = 0.0003) at 11–13 days
for tedizolid and linezolid, respectively. Other
hematologic laboratory abnormalities notable
were absolute neutrophil counts less than the
lower limit of normal reported in 1.9% of those
taking tedizolid and 3.3% of those taking
linezolid at EOT, and hemoglobin levels less
than the lower limit of normal in 28.9% and
31.1% of patients at EOT for tedizolid and
linezolid, respectively. In general, TEAEs were
mild with only 0.5% of patients receiving
tedizolid and 0.9% of those receiving linezolid
discontinuing therapy due to adverse events.
Based on these data, once-daily tedizolid for
6 days was observed to be non-inferior to twice-
daily linezolid for 10 days for the treatment of
ABSSSI. Although both agents were well
tolerated, significantly fewer gastrointestinal
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adverse events and less thrombocytopenia
occurred in the tedizolid group.
Tedizolid phosphate is also currently under
investigation for use in the treatment of
nosocomial pneumonia due to Gram-positive
microorganisms. Over 230 institutions across
six continents will be enrolling patients
through the end of 2016. Seven days of
tedizolid phosphate 200 mg daily will be
compared to 10 days of linezolid 600 mg twice
daily in this randomized, double-blind, Phase
III trial. Therapy with either agent will be
extended to 14 days if concomitant bacteremia
is present. To date, no results from this study
have been reported.
SAFETY
The current safety profile of tedizolid phosphate
is limited to experience in approximately 1000
patients [41, 50–53]. Hematologic laboratory
abnormalities have repeatedly been reported
with the oxazolidinone class.
Thrombocytopenia is the most notable
hematologic effect associated with linezolid
and can be treatment limiting. A Phase I trial
examining the effect of 200, 300, or 400 mg of
tedizolid phosphate daily compared to 600 mg
of linezolid twice daily for 21 days in healthy
volunteers found less thrombocytopenia in the
200 mg tedizolid group (mean reduction 15%
versus 22% for tedizolid and linezolid,
respectively; data presented in poster form by
Prokocimer and colleagues at the 48th Annual
Interscience Conference on Antimicrobial
Agents and Chemotherapy) Higher doses of
tedizolid, however, were not found to be
different when compared to linezolid. In the
Phase III ESTABLISH studies, more patients
receiving linezolid (12.6%) exhibited platelet
counts\150,000 cells/mm3 than in the
tedizolid group (6.4%) through last dose of
study drug (P = 0.0016) [50–52]. Other
hematologic laboratory abnormalities were
similar between groups at the EOT.
Linezolid has also been reported to be
associated with peripheral and optic
neuropathies. This effect, typically reported
following longer courses of therapy, is
hypothesized to be associated with inhibition
of mitochondrial protein synthesis (MPS) [54]
While there currently are no published cases of
tedizolid therapy extending beyond 21 days,
Phase III trials have observed similar rates of
neuropathies for tedizolid and linezolid
(peripheral: 1.2% versus 0.6%, optic: 0.3%
versus 0.2%, respectively) given in shorter
courses. A recent study extensively examined
in vitro and in vivo effects of tedizolid relevant
to neuropathy [55]. In this study, tedizolid was
administered to rats for 9 months and dosed to
achieve AUC around eightfold higher than that
observed in human subjects receiving the
approved 200 mg daily dosing. No neuropathy
was detected in any of the rats at the conclusion
of therapy. In vitro data, however, showed a
significantly lower MPS 50% inhibitory
concentration (IC50) for tedizolid compared to
that of linezolid (0.3 versus 6 lM respectively),
suggesting increased risk of neurotoxicity. The
investigators utilized human pharmacokinetic
data and Monte Carlo simulations to further
evaluate this discrepancy in findings.
Interestingly, significant periods of systemic-
free concentrations of tedizolid, but not
linezolid, below the respective IC50 were
observed. While free linezolid concentrations
drop below the measured MPS IC50 in only 38%
of patients for less than 1 h, free tedizolid
concentrations fall below this level for just
under 8 h in more than 80% of patients. This
sub-IC50 period is hypothesized to allow for
mitochondrial recovery and may account for
10 Infect Dis Ther (2015) 4:1–14
the lack of neuropathies observed in vivo. As
with linezolid, the potential of neuropathies
associated with tedizolid therapy will largely be
defined by Phase IV experience.
An additional safety concern among the
oxazolidinone class is the ability of these
agents to inhibit MAO, resulting in
interactions with other medications and
certain foods, and potentially leading to the
development of serotonin syndrome. The FDA
issued a warning on the label of linezolid to
caution clinicians of this possible effect if given
concurrently with other agents that increase
serotonin including selective serotonin
reuptake inhibitors and serotonin–
norepinephrine reuptake inhibitors. To
evaluate the effects of tedizolid on MAO, IC50
for MAO-A and MAO-B enzymes were
determined in vitro [13]. Tedizolid was found
to be a weak, reversible inhibitor of MAO-A and
MAO-B activity with only minimal effects
observed with the prodrug, tedizolid
phosphate. Additionally, tedizolid was studied
in 30 human subjects concomitantly given
tyramine to test the dose needed to increase
blood pressure by 30 mmHg compared to
placebo. The median dose needed to elicit this
effect was 325 mg of tedizolid phosphate
compared to 425 mg of placebo, resulting in a
clinically irrelevant sensitivity ratio of 1.33 (C2
considered clinically relevant) [13]. Finally,
tedizolid was compared to linezolid in a
murine serotonergic model to evaluate the
effect on mouse head twitching seen when
these oxazolidinones were given with other
medications known to increase serotonin. This
model showed that tedizolid did not increase
head twitch response even when dosed at 25
times the normal human dose. Based on these
studies, tedizolid is thought to have a low
probability of causing MAO-related adverse
events when given in combination with
serotonin-increasing medications. However,
clinical experience with this potential adverse
effect of tedizolid is currently lacking as patients
on medications such as these were excluded
from the Phase III trials.
CONCLUSION
Tedizolid phosphate is the first of the second-
generation oxazolidinones to receive FDA
approval and is currently indicated for the
treatment of ABSSSI and under investigation
for the treatment of hospital acquired
pneumonia. While greatly similar to linezolid,
tedizolid phosphate possesses more favorable
pharmacokinetics, enhanced antimicrobial
potency, and lower incidence of adverse effects
including thrombocytopenia. Clinical
experience with tedizolid, however, is largely
limited to Phase II and III clinical trials, and
careful consideration of therapeutic alternatives
should be recommended. It remains to be seen
if the in vitro activity of tedizolid against some
linezolid-resistant isolates will prove clinically
useful.
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